APA (7th ed.) Citation

S, J., RF, S., C, H., SSL, R. P., M, B., M, P., . . . HR, S. (2024). Protocol of a first-in-human clinical trial to evaluate the safety, tolerability, and preliminary efficacy of the bispecific CD276xCD3 antibody CC-3 in patients with colorectal cancer (CoRe_CC-3). Frontiers in oncology, 14, 1351901. https://doi.org/10.3389/fonc.2024.1351901

Chicago Style (17th ed.) Citation

S, Jung, et al. "Protocol of a First-in-human Clinical Trial to Evaluate the Safety, Tolerability, and Preliminary Efficacy of the Bispecific CD276xCD3 Antibody CC-3 in Patients with Colorectal Cancer (CoRe_CC-3)." Frontiers in Oncology 14 (2024): 1351901. https://doi.org/10.3389/fonc.2024.1351901.

MLA (9th ed.) Citation

S, Jung, et al. "Protocol of a First-in-human Clinical Trial to Evaluate the Safety, Tolerability, and Preliminary Efficacy of the Bispecific CD276xCD3 Antibody CC-3 in Patients with Colorectal Cancer (CoRe_CC-3)." Frontiers in Oncology, vol. 14, 2024, p. 1351901, https://doi.org/10.3389/fonc.2024.1351901.